FGFR2
About
Location: 10q26.13
Mappings
Biomarkers
FGFR2 is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| FGFR2::v | Rearrangement | 4 | 6 |
| FGFR2::BICC1 | Rearrangement | 1 | 2 |
| FGFR2::CASP7 | Rearrangement | 1 | 2 |
| FGFR2 rearrangements | Rearrangement | 3 | 4 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (1) | FGFR2::v | Intrahepatic Cholangiocarcinoma | Futibatinib | |
| FDA (1) | FGFR2::v | Cholangiocarcinoma | Infigratinib | |
| FDA (1) | FGFR2::v | Cholangiocarcinoma | Pemigatinib | |
| EMA (1) HSE (1) | FGFR2::v | Intrahepatic Cholangiocarcinoma | Elacestrant | |
| EMA (1) HSE (1) | FGFR2::BICC1 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) HSE (1) | FGFR2::CASP7 | Bladder Urothelial Carcinoma | Erdafitinib | |
| FDA (1) | FGFR2 rearrangements | Cholangiocarcinoma | Pemigatinib | |
| EMA (1) | FGFR2 rearrangements | Intrahepatic Cholangiocarcinoma | Futibatinib | |
| EMA (1) HSE (1) | FGFR2 rearrangements | Intrahepatic Cholangiocarcinoma | Elacestrant |